ArticleCureus2025
Undifferentiated Carcinoma of the Pancreas With Osteoclast-Like Giant Cells Localized in the Main Pancreatic Duct Without Extraductal Invasion: A Case Report and Literature Review.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Undifferentiated Carcinoma with Osteoclast-Like Giant Cells Associated with CarcinomaSurgical case reports · 2026Article
- Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas: a rare case report and review of the literature.Frontiers in surgery · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Undifferentiated carcinoma with osteoclast-like giant cells (UC-OGC) is a rare pancreatic tumor and typically presents as a giant hypervascular tumor with rapid growth and intratumoral hemorrhage. UC-OGC localized in the main pancreatic duct (MPD) without extraductal invasion is extremely rare and difficult to diagnose preoperatively. Although the tumor rapidly increases in size and often becomes too large for resection, patients with UC-OGC who undergo curative resection show a better prognosis than those with other types of undifferentiated carcinomas and pancreatic ductal adenocarcinoma (PDAC). We must recognize that UC-OGC could present as an MPD-localized tumor and, therefore, should not miss the chance for resection. In this study, we present an unusual case of UC-OGC that was completely localized in the MPD without extraductal invasion. A 77-year-old Japanese man presented to our hospital with excessive thirst. Blood tests showed elevated glycosylated hemoglobin levels (11.9%). Carcinoembryonic antigen, carbohydrate antigen 19-9, Duke pancreatic monoclonal antigen type 2, Span-1, and neuron-specific enolase levels were within normal ranges. Contrast-enhanced computed tomography (CT) showed a 22-mm indistinct nodule with prolonged enhancement in the pancreatic body and dilatation of the distal MPD. Fluorine-18-fluorodeoxyglucose positron-emission tomography with CT showed uptake at the nodule but no evidence of metastasis. Endoscopic ultrasonography showed that the tumor was a heterogeneous hypoechoic nodule localized in the MPD. Pancreatic juice cytology indicated atypical cells but no evidence of malignancy. We suspected PDAC, acinar cell carcinoma, or an intraductal tubulopapillary neoplasm. We performed laparoscopic distal pancreatectomy and splenectomy, along with lymph node dissection. Histopathological examination revealed a 30-mm intraductal tumor with intratumoral hemorrhage, fibrosis, and angiogenesis. The tumor was composed of atypical spindle cells that were partly positive for cytokeratin AE1/3, CAM5.2, and vimentin and scattered osteoclast-like multinucleated giant cells that were positive for CD68. The tumor was completely localized to the MPD without extraductal invasion or lymph node metastasis. The patient received tegafur, gimeracil, and oteracil potassium as postoperative adjuvant chemotherapy for six months and has been recurrence-free for more than five years. UC-OGC demonstrates rapid growth; however, a good prognosis can be expected with curative resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.